Novelion Therapeutics Inc. announced that the implementation of the Company's voluntary liquidation (the “Liquidation”) commenced at 5:00 p.m. Pacific Time, January 16, 2020 (the “Effective Date”). Concurrent with the Liquidator's appointment: Michael Price, previously Executive Vice President, Chief Financial Officer and sole executive officer and employee of the Company, resigned his positions, and Michael Price, Suzanne Bruhn, and Stephen Sabba resigned as directors of the Company.